The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands
BACKGROUND: Atrial fibrillation (AF) causes a significant health and economic burden to the Dutch society. Dabigatran was proven to have at least similar efficacy and a similar or better safety profile when compared to vitamin K antagonists (VKAs) in preventing arterial thromboembolism in patients with AF. OBJECTIVE: To evaluate the cost-effectiveness and monetary benefit of dabigatran versus VKAs in Dutch patients with non-valvular AF. Value-based pricing considerations and corresponding negotiations on dabigatran will be explicitly considered. METHODS: The base case economic analysis was con... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2018 |
Reihe/Periodikum: | van Hulst , M , Stevanovic , J , Jacobs , M S , Tieleman , R G , Kappelhoff , B & Postma , M J 2018 , ' The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands ' , Journal of Medical Economics , vol. 21 , no. 1 , pp. 38-46 . https://doi.org/10.1080/13696998.2017.1372222 |
Schlagwörter: | Cost-effectiveness / value based pricing / dabigatran / atrial fibrillation / warfarin / acenocoumarol / fenprocoumon / RE-LY TRIAL / STROKE PREVENTION / SYSTEMIC EMBOLISM / RISK-FACTORS / ANTICOAGULATION / PREVALENCE / ETEXILATE / INTENSITY / SAFETY |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26825877 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://hdl.handle.net/11370/8b5a5c99-0d4c-4952-96c0-fea3564b588e |